Q-omics provides the consensus-scored SETP11 profile across patient tissues and cancer cell-line models. SETP11 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SETP11 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, SETP11 RNA expression shows 12,286 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where SETP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SETP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SETP11 survival associations across molecular data types. SETP11 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SETP11 RNA expression–survival associations across cancer types. High SETP11 expression shows unfavorable associations in MESO, LIHC, TGCT and DLBC, but favorable associations in LUAD and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SETP11 RNA expression.
This table summarizes SETP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SETP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SETP11 shows lower tumor expression in ESCA and higher tumor expression in KIRC and UCEC. The KIRC box plot shows higher SETP11 RNA expression in tumor versus normal tissue (log2 FC = +0.032, t-test p = .012).
This table shows molecular features associated with SETP11 in patient tissues and cancer cell lines. In patient samples, SETP11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
